Linseed oil (purity ≥99%) was purchased from Aladdin (Shanghai, China). Ciprofibrate (molecular weight = 289.15; purity >98%) was obtained from Aladdin (Shanghai, China). Enteric-coated aspirin was purchased from Bayer Healthcare Co. Ltd. (Beijing, China). Rat ELISA kits for 6-keto-prostaglandin F1α (6-keto-PGF1α), thromboxane B2 (TXB2), tissue plasminogen activator (tPA), and plasminogen activator inhibitor (PAI) were acquired from RuiDaHengHui Science & Technology Development Co., Ltd. (Beijing, China). Human assay kits for fibrinogen (FIB) content were obtained from Mantino Medical Devices Co., Ltd. (Changchun, China). TRIzol (155960-18) was purchased from Ambin (Beijing, China). Triphenyltetrazolium chloride (TTC) Solution (2%) was purchased from Solarbio (Beijing, China). Red Blood Cell Lysis Buffer (C3702) and DEPC water (R0022) were provided by Beyotime (Shanghai, China). PrimeScript™ RT Master Mix (Perfect Real Time) (RR036A) and TB Green Premix Ex Taq II (Tli RNaseH Plus) (2X) (RR036A) were purchased from Takara (Beijing, China).
Enteric coated aspirin
Manufactured by Bayer
Sourced in China, Japan
Enteric-coated aspirin is a type of laboratory equipment designed to protect the active ingredient, aspirin, from the acidic environment of the stomach. This coating allows the aspirin to be released further down the gastrointestinal tract, often in the small intestine. The enteric coating helps minimize potential stomach irritation associated with regular aspirin use.
Automatically generated - may contain errors
4 protocols using enteric coated aspirin
1
Antiplatelet and Fibrinolytic Evaluation
2
Venous Thromboembolism Prophylaxis Strategies
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The patients in cohort 1 received aggressive prophylaxis with either enoxaparin (40 mg, subcutaneous, daily for 2–4 weeks) or rivaroxaban (10 mg, oral, daily for 14–21 days).
The medical charts of patients in cohort 2 were reviewed, and patients with one or more of the following risk factors were assigned to the high‐risk group: a history of prior DVT or PE, a history of cancer, a body mass index of >35 kg/m2, or current smoker. These patients received aggressive prophylaxis with either enoxaparin (40 mg, subcutaneous, daily for 2–4 weeks), or rivaroxaban (10 mg, oral, daily for 14–21 days). Patients with no risk factors were deemed a standard risk and placed on the LMWH and ASA protocol. Standard‐risk patients were instructed to receive enoxaparin (40 mg, subcutaneous, daily for 3 days). Then, for sequential, a 100‐mg enteric‐coated aspirin (Bayer) was given once daily for 30 days. All patients received an intermittent pneumatic foot vein pump and stretched socks for the period until discharge.
The medical charts of patients in cohort 2 were reviewed, and patients with one or more of the following risk factors were assigned to the high‐risk group: a history of prior DVT or PE, a history of cancer, a body mass index of >35 kg/m2, or current smoker. These patients received aggressive prophylaxis with either enoxaparin (40 mg, subcutaneous, daily for 2–4 weeks), or rivaroxaban (10 mg, oral, daily for 14–21 days). Patients with no risk factors were deemed a standard risk and placed on the LMWH and ASA protocol. Standard‐risk patients were instructed to receive enoxaparin (40 mg, subcutaneous, daily for 3 days). Then, for sequential, a 100‐mg enteric‐coated aspirin (Bayer) was given once daily for 30 days. All patients received an intermittent pneumatic foot vein pump and stretched socks for the period until discharge.
3
Antithrombotic-Induced OGIB: VCE Assessment
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The study included patients taking antithrombotics who underwent VCE for OGIB between January 2007 and July 2018. For every patient, abdominal ultrasonography, upper GI endoscopy, and total colonoscopy were performed within one month before VCE, and the origin of GI bleeding was not diagnosed. All patients with at least a 3-month history of the usage of 100 mg enteric-coated aspirin (Bayer Health Care, Osaka, Japan) and/or antithrombotics were included. Recent and present users of non-steroidal anti-inflammatory drugs (NSAIDs) were excluded. Patients were also excluded if they had been identified as having lesions causing small bowel bleeding, such as malignant, tumorous, inflammatory, or vascular lesions, except for ulcers or erosions.
The study was approved by the Research Ethics Committee of Kawasaki Medical School, Okayama, Japan. The study protocol was consistent with the ethical guidelines of the 1975 Declaration of Helsinki as reflected in its prior approval by the institution's human research committee, and the patients were informed using posters and our website (https://h.kawasaki-m.ac.jp/data/dept_022/ekigaku_s_dtl/ ). An opportunity to opt out was always available.
The study was approved by the Research Ethics Committee of Kawasaki Medical School, Okayama, Japan. The study protocol was consistent with the ethical guidelines of the 1975 Declaration of Helsinki as reflected in its prior approval by the institution's human research committee, and the patients were informed using posters and our website (
4
Cementless THA with Aspirin Thromboprophylaxis
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All patients included in this study underwent cementless THA using the posterior-lateral approach under general anesthesia. Two experienced orthopedic surgeons performed the surgical procedures. Surgical techniques and prosthetics were used at the clinical discretion of the attending surgeons. Tranexamic acid was used routinely during each surgical procedure, with an adjusted dose of 15 mg/kg intravenously before incision, and another topical dose before wound closure. No drainage was used in this study.
After surgery, patients received 5 weeks of thromboprophylaxis with either an experimental aspirin regimen or rivaroxaban control. At least 6 h post-operatively, patients in the experimental group started on 100 mg of enteric-coated aspirin (Bayer S.p.A. Italia) twice daily, whereas patients in the control group were administered 10 mg rivaroxaban (Bayer AG, Leverkusen, Germany). All patients received post-operative pneumatic compression during their hospital stay.
Crutch-assisted partial weight-bearing ambulation was started on post-operative day 1 (POD 1). All patients were monitored after surgery and regularly discharged to rehabilitation centers between PODs 3 and 5. Outpatient follow-up was scheduled for PODs 30 and 90. All complications and VTE identified at follow-up were appropriately managed until complete resolution.
After surgery, patients received 5 weeks of thromboprophylaxis with either an experimental aspirin regimen or rivaroxaban control. At least 6 h post-operatively, patients in the experimental group started on 100 mg of enteric-coated aspirin (Bayer S.p.A. Italia) twice daily, whereas patients in the control group were administered 10 mg rivaroxaban (Bayer AG, Leverkusen, Germany). All patients received post-operative pneumatic compression during their hospital stay.
Crutch-assisted partial weight-bearing ambulation was started on post-operative day 1 (POD 1). All patients were monitored after surgery and regularly discharged to rehabilitation centers between PODs 3 and 5. Outpatient follow-up was scheduled for PODs 30 and 90. All complications and VTE identified at follow-up were appropriately managed until complete resolution.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!